Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Clinical tool

CISNE Score in Clinically Stable Febrile Neutropenia

Risk of serious complications in solid-tumour patients who look stable

Updated: 27 October 20261 min read2 references

For clinically stable patients with solid tumours and febrile neutropenia (complements MASCC).

This calculator needs JavaScript; the formula and its interpretation are in the text of this page.

An aid for clinicians; it does not replace clinical judgement, local protocols or the drug label. Double-check every result before prescribing.

Use

CISNE was developed for solid-tumour patients on moderately intensive chemotherapy who appear stable at presentation; in this group MASCC labels many high-risk patients as low risk [1]. In the validation study, serious complications occurred in about 1.1%, 6.2% and 36% of classes I (score 0), II (1–2) and III (3 or more) [1].

The ASCO/IDSA guideline suggests CISNE to identify outpatient candidates among stable solid-tumour patients [2].

Variable definitions [1]
VariableDefinition
ECOG 2 or morePerformance status
Stress hyperglycaemiaGlucose 121 mg/dL or more without diabetes, or 251 mg/dL or more with diabetes, or need to intensify treatment
Cardiovascular diseaseHeart failure, coronary disease, arrhythmia or valvular disease
MucositisGrade 2 or more
MonocytesBelow 200/µL

References

2 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE studyCarmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al · J Clin Oncol · 2015;33:465-71
    DOIPubMed Back to text: 1 2 3
  2. 2
    Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline UpdateTaplitz RA, Kennedy EB, Bow EJ, et al · J Clin Oncol · 2018;36:1443-1453
    Study cardDOIPubMed Back to text

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/tools/cisne-score/

Related pages

27 October 2026 ANC Calculator (Absolute Neutrophil Count) Absolute neutrophil count (ANC) calculator with CTCAE neutropenia grading, the definition of febrile neutropenia and what to do immediately. 27 October 2026 MASCC Score for Febrile Neutropenia MASCC risk index calculator for febrile neutropenia and the criteria for oral outpatient treatment per the ASCO/IDSA guideline. 27 October 2026 G-CSF Prophylaxis: Is It Needed? Decision aid for prophylactic G-CSF (filgrastim, pegfilgrastim) based on the febrile neutropenia risk of the regimen and patient risk factors, following ASCO and EORTC.